Synpromics Appoints Sarah Haecker Meeks as VP of BD

Dr. Haecker Meeks brings a deep expertise in emerging technologies and business strategy focused on the design and development of gene medicines and will lead business development for the company.

“Sarah’s experience is an ideal fit for the Synpromics’ leadership team as we continue to enable therapeutic applications of our synthetic promoter platform,” commented Dr David Venables, Chief Executive Officer of Synpromics Ltd. “She brings the unique combination of deep technical expertise and strategic business acumen optimal for positioning and partnering Synpromics’ platform technology. We’re pleased to have her continue to build upon our nearly 20 current partnerships and support the rapidly expanding use of novel synthetic promoters and gene regulation in gene and cell therapies.”

“I am thrilled to join Synpromics to continue to drive the identification and implementation of new platform applications,” added Sarah Haecker Meeks, “I’m excited about the opportunity to contribute to a company that is poised to revolutionise the way that gene and cell medicines are designed and delivered across multiple therapeutic programmes to advance treatments for numerous diseases.”

Synpromics has also established a new US subsidiary, Synpromics Inc. and Sarah will lead business development activities from the US covering all territories.